Get the Stockscreener App
27.64
1.71%
-0.48
After Hours:
27.66
0.02
+0.07%
Galapagos Nv Adr stock is traded at $27.64, with a volume of 54,552.
It is down -1.71% in the last 24 hours and down -3.15% over the past month.
See More
Previous Close:
$28.12
Open:
$27.87
24h Volume:
54,552
Relative Volume:
0.28
Market Cap:
$1.69B
Revenue:
$282.04M
Net Income/Loss:
$221.88M
P/E Ratio:
-11.79
EPS:
-2.3434
Net Cash Flow:
$-449.57M
1W Performance:
+1.88%
1M Performance:
-3.15%
6M Performance:
+2.60%
1Y Performance:
-25.22%
1-Day Range:
$27.62
$27.93
1-Week Range:
$26.87
$28.48
52-Week Range:
$24.16
$42.45
Galapagos Nv Adr Stock (GLPG) Company Profile
Compare GLPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
27.64 | 1.69B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Downgrade | Kepler | Hold → Reduce |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-02-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-28-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-24-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-23 | Upgrade | Jefferies | Underperform → Hold |
| Nov-07-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-27-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-19-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Apr-14-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-23-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Feb-19-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-19-20 | Initiated | Maxim Group | Buy |
| Oct-21-20 | Downgrade | Goldman | Neutral → Sell |
| Aug-25-20 | Downgrade | Jefferies | Buy → Hold |
| Aug-24-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-19-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| Jul-10-20 | Downgrade | Stifel | Buy → Hold |
| Mar-30-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-25-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Jan-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-02-19 | Initiated | BofA/Merrill | Neutral |
| Sep-09-19 | Resumed | Morgan Stanley | Overweight |
| Jul-31-19 | Upgrade | UBS | Neutral → Buy |
| Jul-29-19 | Downgrade | Jefferies | Buy → Hold |
View All
Galapagos Nv Adr Stock (GLPG) Latest News
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Galapagos receives transparency notification from EcoR1 Capital - GlobeNewswire Inc.
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.32% By Investing.com - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com India
Galapagos NV shares poised for outperformance, says TD Cowen By Investing.com - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.79% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.79% - Investing.com India
Belgium stocks higher at close of trade; BEL 20 up 1.28% By Investing.com - Investing.com
Belgium shares higher at close of trade; BEL 20 up 1.28% - Investing.com India
Belgium stocks lower at close of trade; BEL 20 down 0.40% By Investing.com - Investing.com
Belgium shares lower at close of trade; BEL 20 down 0.40% - Investing.com India
Adaptimmune and Galapagos partner on cancer therapy By Investing.com - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com India
Earnings call: Galapagos outlines strategic focus in Q1 2024 results By Investing.com - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Allied Gaming & Entertainment insider buys shares worth over $456,000 By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target By Investing.com - Investing.com
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA - Yahoo Finance
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integr - Benzinga
Is Galapagos NV (GLPG) A Good Stock To Buy? - Insider Monkey
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Yahoo Finance
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes DividendAlecto - Benzinga
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To DebutStaar S - Benzinga
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOsAmarin Corp (NASDAQ:A - Benzinga
AIM tech shares that broke America - Interactive Investor
25 Stocks Moving In Friday's Pre-Market SessionAlnylam Pharmaceuticals (NASDAQ:ALNY), Aclaris Therapeu - Benzinga
Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - InvestorPlace
25 Stocks Moving In Thursday's Pre-Market SessionAegon (NYSE:AEG) - Benzinga
Galapagos Nv Adr Stock (GLPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):